HSPPC-96 vaccine in metastatic melanoma patients: From the state of the art to a possible future

Giulio Tosti, Alessandra Di Pietro, Pier Francesco Ferrucci, Alessandro Testori

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage®) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.

Original languageEnglish
Pages (from-to)1513-1526
Number of pages14
JournalExpert Review of Vaccines
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Melanoma
Heat-Shock Proteins
Neoplasms
Vaccines
Phase III Clinical Trials
Phase II Clinical Trials
Peptides
Clinical Trials, Phase I
Cancer Vaccines
Kidney Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pancreatic Neoplasms
Non-Hodgkin's Lymphoma
Stomach Neoplasms
Colorectal Neoplasms
Vaccination
vitespin
Clinical Trials
Safety
Therapeutics

Keywords

  • Heat-shock protein
  • HSP
  • HSPPC
  • Metastatic melanoma
  • Oncophage®
  • Vaccine
  • Vitespen

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

HSPPC-96 vaccine in metastatic melanoma patients : From the state of the art to a possible future. / Tosti, Giulio; Di Pietro, Alessandra; Ferrucci, Pier Francesco; Testori, Alessandro.

In: Expert Review of Vaccines, Vol. 8, No. 11, 11.2009, p. 1513-1526.

Research output: Contribution to journalArticle

@article{4333b2a04530445687f43303b8530b90,
title = "HSPPC-96 vaccine in metastatic melanoma patients: From the state of the art to a possible future",
abstract = "Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage{\circledR}) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.",
keywords = "Heat-shock protein, HSP, HSPPC, Metastatic melanoma, Oncophage{\circledR}, Vaccine, Vitespen",
author = "Giulio Tosti and {Di Pietro}, Alessandra and Ferrucci, {Pier Francesco} and Alessandro Testori",
year = "2009",
month = "11",
doi = "10.1586/erv.09.108",
language = "English",
volume = "8",
pages = "1513--1526",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - HSPPC-96 vaccine in metastatic melanoma patients

T2 - From the state of the art to a possible future

AU - Tosti, Giulio

AU - Di Pietro, Alessandra

AU - Ferrucci, Pier Francesco

AU - Testori, Alessandro

PY - 2009/11

Y1 - 2009/11

N2 - Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage®) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.

AB - Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage®) is the first autologous cancer vaccine made from individual patients' tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin's lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.

KW - Heat-shock protein

KW - HSP

KW - HSPPC

KW - Metastatic melanoma

KW - Oncophage®

KW - Vaccine

KW - Vitespen

UR - http://www.scopus.com/inward/record.url?scp=70449365432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449365432&partnerID=8YFLogxK

U2 - 10.1586/erv.09.108

DO - 10.1586/erv.09.108

M3 - Article

C2 - 19863242

AN - SCOPUS:70449365432

VL - 8

SP - 1513

EP - 1526

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 11

ER -